Honor Recognizes Companies Advancing Innovative Solutions to Improve Women’s Health and Safety in Emerging Markets Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced that …
Trending at Lumira Ventures
Antiva Biosciences Closes $31 Million Series D Equity Financing
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $31 million Series D equity financing. The financing was supported by a syndicate of premier …
Antiva Biosciences – A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it
August 16, 2018 External Link
Antiva Biosciences Closes $15 Million Series C-1 Financing
SOUTH SAN FRANCISCO, California, /PRNewswire/ — Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $15 million in Series C-1 financing led by Hillhouse Capital Management. Sirona …